Navigation Links
BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins

Accentia Biopharmaceuticals, Inc. report follow-up data to a Phase 2 trial conducted by the National Cancer Institute (NCI) that shows Biovest's BiovaxID yielded an 89% survival rate in mantle cell lymphoma patients.

The median follow-up was 3.8 years. Historically, patients with this type of lymphoma only have had a 50% chance of surviving 3 years and 20% chance of surviving 5 years. BiovaxID, an investigational personalized anti-cancer vaccine, stimulates the immune system to seek out and destroy tumor cells. The data were published in a recent edition of Nature Medicine (Nat Med.2005; 11(9):986-91).

In this single-arm, open-label Phase 2 clinical study, patients with untreated mantle cell non-Hodgkin's lymphoma (NHL) were administered six cycles of dose-adjusted EPOCH-R, a chemotherapy regimen that includes Rituxan® (rituximab). Of the 26 patients in the study, 23 received vaccinations with BiovaxID commencing at least three months after completing their last chemotherapy and Rituxan treatments. Upon the 46-month (3.8-year) follow-up, the overall survival rate was 89%. This study showed that, despite an almost complete depletion of normal B-cell lymphocytes due to EPOCH-R therapy, BiovaxID did induce anti-tumor T-cell lymphocyte responses in most patients. Depletion of normal B-cell lymphocytes is a consequence of the combination of chemotherapy and Rituxan, but not of BiovaxID therapy. Thus, "it is justifiable to administer vaccines in the setting of B-cell depletion, but vaccine boosts after B-cell recovery may be necessary for optimal humoral responses," concluded the investigators.

Lymphocytes are a type of white blood cell. There are two types of lymphocytes: B-cell lymphocytes, which produce antibodies ("humoral" immunity) in response to immune stimulation; and T-cell lymphocytes, which mediate cell responses to immune stimulation ("cellular" immunity). B-cell lymphocytes can undergo malignant transformation to become non-Hogkins lymphoma, multiple myeloma or chronic lymphocytic leukemia.

"This is the first human cancer vaccine study to see T-cell responses in the absence of B-cells," said the study's first author, Sattva Neelapu, M.D., Assistant Professor in the Department of Lymphoma at the University of Texas M. D. Anderson Cancer Center. "This paves the way to use vaccines in a number of hematological cancers that are treated by eliminating diseased B-cells."

Biovest is now enrolling patients in a pivotal Phase 3 trial to test BiovaxID against follicular non-Hodgkin's lymphoma (NHL). Follicular NHL is an indolent (slow-growing) form of lymphoma not considered curable with existing therapies. The impressive findings from the Phase 2 clinical trial using BiovaxID in mantle cell lymphoma suggest the vaccine could potentially be used to treat other types of NHL, in addition to follicular NHL.


'"/>

Source:The Investor Relations Group


Related biology news :

1. Hunger in America rises by 43 percent over last five years
2. Method slashes quantum dot costs by 80 percent
3. Hepatitis B accounts for 40 percent of missing Asian women
4. Vaccine provides 100 percent protection against avian flu virus in animal study
5. Oceans are 70 percent shark free
6. St. Jude projects 90 percent cure rate for ALL
7. Biofuels can replace about 30 percent of fuel needs with significant research and policy effort
8. Psychotropic drug prescriptions for teens surge 250 percent over 7 year period
9. Just the expectation of a mirthful laughter experience boosts endorphins 27 percent, HGH 87 percent
10. Septum keeps neurons in synch, can reduce epileptic seizures by 90 percent
11. One therapeutic dose of radiation causes 30 percent spongy bone loss in mice
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):
(Date:6/15/2017)... Philadelphia, PA (PRWEB) , ... June 15, 2017 ... ... Center’s Esther Klein Gallery (EKG) follows an artist’s journey through creative experimentation and ... 22, 2017 and runs through July 22nd. An opening reception will be held ...
(Date:6/15/2017)... ... June 15, 2017 , ... DuPont Industrial Biosciences (DuPont) announced ... at Bloomberg’s 2017 Sustainable Business Summit: Seattle this Thursday, June 15, ... on a panel titled “Developing a Corporate Renewables Strategy.” , “Consumers want ...
(Date:6/14/2017)... ... 14, 2017 , ... Slone Partners welcomed a panel of ... executive search firm, “Building Value in Precision Medicine: Can We Overcome the Obstacles?” ... led an open discussion with expert panelists Troy Cox, CEO of Foundation Medicine, ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... materials for pumps and process equipment, has appointed Andrew Ondish as Territory Sales ... Ondish holds a B.S. degree in Petroleum Engineering from Colorado School of Mines. ...
Breaking Biology Technology: